Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1

Journal of Controlled Release

Volumn 157, Issue 1, 2012, Pages 132-140

  Chung, Woon Gye ^a   Sandoval, Michael A ^a   Sloat, Brian R ^a   Lansakara P, Dharmika S P ^a   Cui, Zhengrong ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Cytotoxicity; Deoxycytidine kinase; In vivo anti tumor activity; Nucleoside transporter; Proteomics; siRNA

Indexed keywords

DEOXYCYTIDINE KINASE; IN VIVO ANTI-TUMOR ACTIVITY; NUCLEOSIDE TRANSPORTERS; PROTEOMICS; SIRNA;

BIOMOLECULES; CELL CULTURE; CELL DEATH; CHEMOTHERAPY; COMPUTATIONAL ELECTROMAGNETICS; CYTOTOXICITY; ENZYME INHIBITION; NANOPARTICLES; TUMORS;

DRUG PRODUCTS;

CASPASE; GEMCITABINE; NANOPARTICLE; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1; STEARIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER RESISTANCE; CONTROLLED STUDY; CYTOTOXICITY; DRUG FORMULATION; ENZYME ACTIVATION; FEMALE; GROWTH REGULATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; TUMOR CELL LINE; WILD TYPE;

ANIMALS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MICE; MICE, NUDE; NANOPARTICLES; RANDOM ALLOCATION; STEARATES; TUMOR SUPPRESSOR PROTEINS;

EID: 84855847439     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.08.004     Document Type: Article

References (50)

1. S.B. Kaye Gemcitabine: current status of phase I and II trials J. Clin. Oncol. 12 1994 1527 1531 (Pubitemid 24244984)
2. V. Heinemann, Y.Z. Xu, S. Chubb, A. Sen, L.W. Hertel, G.B. Grindey, and W. Plunkett Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine Mol. Pharmacol. 38 1990 567 572 (Pubitemid 20356209)
3. C.J. van Moorsel, G. Veerman, A.M. Bergman, A. Guechev, J.B. Vermorken, P.E. Postmus, and G.J. Peters Combination chemotherapy studies with gemcitabine Semin. Oncol. 24 1997 S7-17-S17-23
4. G.J. Peters, C.L. van der Wilt, C.J. van Moorsel, J.R. Kroep, A.M. Bergman, and S.P. Ackland Basis for effective combination cancer chemotherapy with antimetabolites Pharmacol. Ther. 87 2000 227 253
5. C.J. van Moorsel, G.J. Peters, and H.M. Pinedo Gemcitabine: future prospects of single-agent and combination studies Oncologist 2 1997 127 134 (Pubitemid 27263944)
6. R. Andersson, U. Aho, B.I. Nilsson, G.J. Peters, M. Pastor-Anglada, W. Rasch, and M.L. Sandvold Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions Scand. J. Gastroenterol. 44 2009 782 786
7. J.R. Mackey, R.S. Mani, M. Selner, D. Mowles, J.D. Young, J.A. Belt, C.R. Crawford, and C.E. Cass Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines Cancer Res. 58 1998 4349 4357 (Pubitemid 28450036)
8. J. Garcia-Manteiga, M. Molina-Arcas, F.J. Casado, A. Mazo, and M. Pastor-Anglada Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidine- induced cytotoxicity Clin. Cancer Res. 9 2003 5000 5008 (Pubitemid 37323307)
9. A.M. Bergman, H.M. Pinedo, and G.J. Peters Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine) Drug Resist. Updat. 5 2002 19 33
10. P. Huang, S. Chubb, L.W. Hertel, G.B. Grindey, and W. Plunkett Action of 2′,2′-difluorodeoxycytidine on DNA synthesis Cancer Res. 51 1991 6110 6117
11. S. Pereira, P.A. Fernandes, and M.J. Ramos Mechanism for ribonucleotide reductase inactivation by the anticancer drug gemcitabine J. Comput. Chem. 25 2004 1286 1294
12. T. Neff, and C.A. Blau Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine Exp. Hematol. 24 1996 1340 1346 (Pubitemid 26348932)
13. D.Y. Bouffard, J. Laliberte, and R.L. Momparler Kinetic studies on 2′,2′-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase Biochem. Pharmacol. 45 1993 1857 1861 (Pubitemid 23150977)
14. Y.G. Goan, B. Zhou, E. Hu, S. Mi, and Y. Yen Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2- difluorodeoxycytidine in the human KB cancer cell line Cancer Res. 59 1999 4204 4207 (Pubitemid 29418726)
15. J.D. Davidson, L. Ma, M. Flagella, S. Geeganage, L.M. Gelbert, and C.A. Slapak An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines Cancer Res. 64 2004 3761 3766 (Pubitemid 38697284)
16. M.Y. Cao, Y. Lee, N.P. Feng, K. Xiong, H. Jin, M. Wang, A. Vassilakos, S. Viau, J.A. Wright, and A.H. Young Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma Clin. Cancer Res. 9 2003 4553 4561 (Pubitemid 37248415)
17. A.M. Bergman, P.P. Eijk, V.W. Ruiz van Haperen, K. Smid, G. Veerman, I. Hubeek, P. van den Ijssel, B. Ylstra, and G.J. Peters In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant Cancer Res. 65 2005 9510 9516 (Pubitemid 41508021)
18. R. Rosell, K.D. Danenberg, V. Alberola, G. Bepler, J.J. Sanchez, C. Camps, M. Provencio, D. Isla, M. Taron, P. Diz, and A. Artal Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients Clin. Cancer Res. 10 2004 1318 1325 (Pubitemid 38365223)
19. P. Ceppi, M. Volante, S. Novello, I. Rapa, K.D. Danenberg, P.V. Danenberg, A. Cambieri, G. Selvaggi, S. Saviozzi, R. Calogero, M. Papotti, and G.V. Scagliotti ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine Ann. Oncol. 17 2006 1818 1825 (Pubitemid 44884058)
20. K. Ohtaka, N. Kohya, K. Sato, Y. Kitajima, T. Ide, M. Mitsuno, and K. Miyazaki Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma Oncol. Rep. 20 2008 279 286
21. M. Schirmer, A.P. Stegmann, F. Geisen, and G. Konwalinka Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5′-nucleotidase activity Exp. Hematol. 26 1998 1223 1228 (Pubitemid 28541765)
22. A.M. Bergman, A.D. Adema, J. Balzarini, S. Bruheim, I. Fichtner, P. Noordhuis, O. Fodstad, F. Myhren, M.L. Sandvold, H.R. Hendriks, and G.J. Peters Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models Invest. New Drugs 29 2011 456 466
23. P. Chen, P.Y. Chien, A.R. Khan, S. Sheikh, S.M. Ali, M.U. Ahmad, and I. Ahmad In-vitro and in-vivo anti-cancer activity of a novel gemcitabine- cardiolipin conjugate Anticancer Drugs 17 2006 53 61
24. R.L. Alexander, B.T. Greene, S.V. Torti, and G.L. Kucera A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms Cancer Chemother. Pharmacol. 56 2005 15 21 (Pubitemid 41201751)
25. C.M. Hu, and L. Zhang Therapeutic nanoparticles to combat cancer drug resistance Curr. Drug Metab. 10 2009 836 841
26. L.H. Reddy, C. Dubernet, S.L. Mouelhi, P.E. Marque, D. Desmaele, and P. Couvreur A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types J. Control. Release 124 2007 20 27 (Pubitemid 350103730)
27. B.R. Sloat, M.A. Sandoval, D. Li, W.G. Chung, P.D. Lansakara, P.J. Proteau, K. Kiguchi, J. DiGiovanni, and Z. Cui In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles Int. J. Pharm. 409 2011 278 288
28. V.W. Ruiz van Haperen, G. Veerman, S. Eriksson, E. Boven, A.P. Stegmann, M. Hermsen, J.B. Vermorken, H.M. Pinedo, and G.J. Peters Development and molecular characterization of a 2′,2′-difluorodeoxycytidine- resistant variant of the human ovarian carcinoma cell line A2780 Cancer Res. 54 1994 4138 4143
29. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 22 1984 27 55
30. W.G. Chung, C.L. Miranda, and C.S. Maier Detection of carbonyl-modified proteins in interfibrillar rat mitochondria using N′- aminooxymethylcarbonylhydrazino-D-biotin as an aldehyde/keto-reactive probe in combination with Western blot analysis and tandem mass spectrometry Electrophoresis 29 2008 1317 1324 (Pubitemid 351461085)
31. K. Marley, D.T. Mooney, G. Clark-Scannell, T.T. Tong, J. Watson, T.M. Hagen, J.F. Stevens, and C.S. Maier Mass tagging approach for mitochondrial thiol proteins J. Proteome Res. 4 2005 1403 1412 (Pubitemid 41208698)
32. J. Chavez, J. Wu, B. Han, W.G. Chung, and C.S. Maier New role for an old probe: affinity labeling of oxylipid protein conjugates by N′- aminooxymethylcarbonylhydrazino d-biotin Anal. Chem. 78 2006 6847 6854 (Pubitemid 44522535)
33. V.L. Damaraju, S. Damaraju, J.D. Young, S.A. Baldwin, J. Mackey, M.B. Sawyer, and C.E. Cass Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy Oncogene 22 2003 7524 7536 (Pubitemid 37487174)
34. M.L. Clarke, J.R. Mackey, S.A. Baldwin, J.D. Young, and C.E. Cass The role of membrane transporters in cellular resistance to anticancer nucleoside drugs Cancer Treat. Res. 112 2002 27 47
35. C.M. Galmarini, J.R. Mackey, and C. Dumontet Nucleoside analogues and nucleobases in cancer treatment Lancet Oncol. 3 2002 415 424 (Pubitemid 36958272)
36. A.V. Leisewitz, E.I. Zimmerman, S.Z. Jones, J. Yang, and L.M. Graves Imatinib-resistant CML cells have low ENT activity but maintain sensitivity to gemcitabine Nucleosides Nucleotides Nucleic Acids 27 2008 779 786 (Pubitemid 351948559)
37. K. Cho, X. Wang, S. Nie, Z.G. Chen, and D.M. Shin Therapeutic nanoparticles for drug delivery in cancer Clin. Cancer Res. 14 2008 1310 1316 (Pubitemid 351413909)
38. E. Wisse, F. Braet, D. Luo, R. De Zanger, D. Jans, E. Crabbe, and A. Vermoesen Structure and function of sinusoidal lining cells in the liver Toxicol. Pathol. 24 1996 100 111 (Pubitemid 26066425)
39. F. Yuan, M. Dellian, D. Fukumura, M. Leunig, D.A. Berk, V.P. Torchilin, and R.K. Jain Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size Cancer Res. 55 1995 3752 3756
40. D. Cecconi, M. Donadelli, A. Scarpa, A. Milli, M. Palmieri, M. Hamdan, L.B. Areces, J. Rappsilber, and P.G. Righetti Proteomic analysis of pancreatic ductal carcinoma cells after combined treatment with gemcitabine and trichostatin A J. Proteome Res. 4 2005 1909 1916 (Pubitemid 41814256)
41. W. Wu, X. Tang, W. Hu, R. Lotan, W.K. Hong, and L. Mao Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry Clin. Exp. Metastasis 19 2002 319 326 (Pubitemid 34606757)
42. K. Moldave Eukaryotic protein synthesis Annu. Rev. Biochem. 54 1985 1109 1149
43. M. Sabbah, S. Emami, G. Redeuilh, S. Julien, G. Prevost, A. Zimber, R. Ouelaa, M. Bracke, O. De Wever, and C. Gespach Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers Drug Resist. Updat. 11 2008 123 151
44. J.P. Thiery Epithelial-mesenchymal transitions in tumour progression Nat. Rev. Cancer 2 2002 442 454
45. A.N. Shah, J.M. Summy, J. Zhang, S.I. Park, N.U. Parikh, and G.E. Gallick Development and characterization of gemcitabine-resistant pancreatic tumor cells Ann. Surg. Oncol. 14 2007 3629 3637 (Pubitemid 350160137)
46. J.A. Wright, A.K. Chan, B.K. Choy, R.A. Hurta, G.A. McClarty, and A.Y. Tagger Regulation and drug resistance mechanisms of mammalian ribonucleotide reductase, and the significance to DNA synthesis Biochem. Cell Biol. 68 1990 1364 1371
47. S. Nakahira, S. Nakamori, M. Tsujie, Y. Takahashi, J. Okami, S. Yoshioka, M. Yamasaki, S. Marubashi, I. Takemasa, A. Miyamoto, Y. Takeda, H. Nagano, K. Dono, K. Umeshita, M. Sakon, and M. Monden Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer Int. J. Cancer 120 2007 1355 1363
48. R. Rosell, J.M. Sanchez, M. Taron, A. O'Brate, J.L. Gutierrez, M. Monzo, E. Felip, J.J. Sanchez, and V. Alberola Novel approaches in the treatment of non-small-cell lung cancer Oncology (Williston Park) 15 2001 52 60 (Pubitemid 33739206)
49. J.M. Reid, W. Qu, S.L. Safgren, M.M. Ames, M.D. Krailo, N.L. Seibel, J. Kuttesch, and J. Holcenberg Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors J. Clin. Oncol. 22 2004 2445 2451 (Pubitemid 41115403)
50. D.M. Bender, J. Bao, A.H. Dantzig, W.D. Diseroad, K.L. Law, N.A. Magnus, J.A. Peterson, E.J. Perkins, Y.J. Pu, S.M. Reutzel-Edens, D.M. Remick, J.J. Starling, G.A. Stephenson, R.K. Vaid, D. Zhang, and J.R. McCarthy Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine J. Med. Chem. 52 2009 6958 6961